Cilta-cel versus conventional treatment in patients with relapse/refractory multiple myeloma.

Luciano J. Costa,Yi Lin,Thomas G. Martin,Saurabh Chhabra,Saad Z. Usmani,Sundar Jagannath,Natalie S. Callander,Jesus G. Berdeja,Yubin Kang,Ravi Vij,Hong Tian,Satish Valluri,Jennifer Marino,Carolyn C. Jackson,Arnob Banerjee,Ankit Kansagra,Jordan M. Schecter,Shaji Kumar,Parameswaran Hari

Cilta-cel versus conventional treatment in patients with relapse/refractory multiple myeloma.

2021

Luciano J. Costa
Yi Lin
Thomas G. Martin
Saurabh Chhabra
Saad Z. Usmani
Sundar Jagannath
Natalie S. Callander
Jesus G. Berdeja
Yubin Kang
Ravi Vij
Hong Tian
Satish Valluri
Jennifer Marino
Carolyn C. Jackson
Arnob Banerjee
Ankit Kansagra
Jordan M. Schecter
Shaji Kumar
Parameswaran Hari

8030Background: CARTITUDE-1 is a single arm study of Ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) anti-BCMA CAR-T cell therapy in US patients (pts) with relapsed multiple myeloma (RRMM) refr...

Keywords:

Refractory Multiple Myeloma
in patient
Internal medicine
Medicine
Oncology
Single Arm Study
Conventional treatment
Cell therapy
Multiple myeloma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations